Free Trial

Artivion (AORT) Stock Price, News & Analysis

Artivion logo
$28.27 +0.24 (+0.86%)
(As of 11/22/2024 ET)

About Artivion Stock (NYSE:AORT)

Key Stats

Today's Range
$28.03
$28.79
50-Day Range
$24.97
$29.41
52-Week Range
$16.48
$30.00
Volume
222,367 shs
Average Volume
231,457 shs
Market Capitalization
$1.19 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.00
Consensus Rating
Buy

Company Overview

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Artivion Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
24th Percentile Overall Score

AORT MarketRank™: 

Artivion scored higher than 24% of companies evaluated by MarketBeat, and ranked 848th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Artivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Artivion has only been the subject of 4 research reports in the past 90 days.

  • Read more about Artivion's stock forecast and price target.
  • Earnings Growth

    Earnings for Artivion are expected to grow by 52.17% in the coming year, from $0.23 to $0.35 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Artivion is -1,413.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Artivion is -1,413.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Artivion has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Artivion's valuation and earnings.
  • Percentage of Shares Shorted

    7.62% of the float of Artivion has been sold short.
  • Short Interest Ratio / Days to Cover

    Artivion has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Artivion has recently increased by 0.33%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Artivion does not currently pay a dividend.

  • Dividend Growth

    Artivion does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.62% of the float of Artivion has been sold short.
  • Short Interest Ratio / Days to Cover

    Artivion has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Artivion has recently increased by 0.33%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Artivion has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Artivion this week, compared to 2 articles on an average week.
  • Search Interest

    Only 1 people have searched for AORT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    Only 1 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $409,501.00 in company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of Artivion is held by insiders.

  • Percentage Held by Institutions

    86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Artivion's insider trading history.
Receive AORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter.

AORT Stock News Headlines

Artivion, Inc. (AORT) Q3 2024 Earnings Call Transcript
Buffett Dumps $982 Million in BofA Stock—What Does He Know?
Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.
Artivion price target raised to $32 from $29.60 at Ladenburg
Artivion (AORT) Gets a Buy from Oppenheimer
Where Artivion Stands With Analysts
Artivion’s Q3 2024: Revenue Growth and Strategic Progress
See More Headlines

AORT Stock Analysis - Frequently Asked Questions

Artivion's stock was trading at $17.88 at the beginning of the year. Since then, AORT shares have increased by 58.1% and is now trading at $28.27.
View the best growth stocks for 2024 here
.

Artivion, Inc. (NYSE:AORT) announced its earnings results on Thursday, February, 17th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.45. The company earned $79.39 million during the quarter, compared to analyst estimates of $78 million. Artivion had a positive trailing twelve-month return on equity of 5.15% and a negative net margin of 0.22%.

Top institutional shareholders of Artivion include Wellington Management Group LLP (3.95%), State Street Corp (3.61%), Geode Capital Management LLC (2.10%) and Royce & Associates LP (2.08%). Insiders that own company stock include James P Mackin, David Ashley Lee, Jean F Holloway, Marshall S Stanton, Andrew M Green, Rochelle L Maney, Dennis B Maier and Matthew A Getz.
View institutional ownership trends
.

Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
2/17/2022
Today
11/24/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/20/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Employees
1,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$31.00
High Stock Price Target
$33.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+9.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-30,690,000.00
Pretax Margin
2.21%

Debt

Sales & Book Value

Annual Sales
$354 million
Cash Flow
$0.77 per share
Book Value
$7.27 per share

Miscellaneous

Free Float
38,524,000
Market Cap
$1.19 billion
Optionable
Optionable
Beta
1.75
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NYSE:AORT) was last updated on 11/24/2024 by MarketBeat.com Staff
From Our Partners